By Fineline Cube Keymed Biosciences Inc. (HKG: 2162) announced that its BCMA×CD3 T cell engager (TCE), CM336 (OM336), has received Breakthrough Therapy Designation (BTD) from China’s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA). The designation covers treatment of relapsed or refractory light chain (AL) amyloidosis in patients who have previously received bortezomib and CD38 monoclonal antibody therapy.
Regulatory Milestone Details
| Parameter | Detail |
|---|---|
| Compound | CM336 (OM336) |
| Mechanism | BCMA×CD3 T cell engager (TCE) |
| Indication | Relapsed/refractory AL amyloidosis |
| Patient Population | Previously treated with bortezomib and CD38 monoclonal antibody |
| Regulatory Authority | CDE/NMPA, China |
| Designation Type | Breakthrough Therapy Designation (BTD) |
This BTD represents a significant advancement for AL amyloidosis treatment, a rare and often fatal condition with limited therapeutic options for relapsed/refractory patients.
Global Development & Partnership Timeline
- 2024: Ouro Medicines (incubated by GlaxoSmithKline and Monograph Capital) licensed CM336 for research, development, manufacturing, and commercialization outside Greater China
- January 2026: CM336 received U.S. FDA Fast Track Designation for autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP)
- March 2026: Gilead Sciences (Nasdaq: GILD) acquired Ouro Medicines for over $2 billion, expected to accelerate global CM336 development
The Gilead acquisition significantly enhances CM336’s global development prospects, providing access to substantial resources and established commercial infrastructure.
Scientific & Clinical Significance
CM336’s BCMA×CD3 T cell engager mechanism represents a novel approach to targeting plasma cell disorders:
- Target Rationale: BCMA (B-cell maturation antigen) is highly expressed on plasma cells, which produce the pathogenic light chains in AL amyloidosis
- T Cell Engagement: CD3 binding redirects T cells to eliminate BCMA-expressing plasma cells
- Unmet Need Addressed: AL amyloidosis patients who fail standard therapies face poor prognosis with median survival of less than 6 months
- Cross-Indication Potential: The same mechanism shows promise in autoimmune conditions (AIHA, ITP), demonstrating broad applicability
Market & Strategic Context
- Rare Disease Focus: AL amyloidosis affects approximately 3,000-4,000 new patients annually in the U.S. alone, with similar prevalence in China
- Premium Pricing Potential: Orphan drug status and breakthrough designations support premium pricing and expedited market access
- Global Partnership Value: Gilead’s $2+ billion investment validates CM336’s commercial potential across multiple indications
- Competitive Positioning: Among the first BCMA-targeted TCEs specifically developed for AL amyloidosis
This latest BTD strengthens Keymed’s position in the emerging T cell engager space and addresses critical unmet needs in both rare hematologic disorders and autoimmune diseases.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and partnership outcomes. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and integration challenges following the Gilead-Ouro transaction.-Fineline Info & Tech